Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Ayers

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
JTO Clinical and Research Reports|February 16, 2023
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLCMarina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
JTO Clinical and Research Reports|October 15, 2025
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]Marina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
Future Oncology (London, England)|July 19, 2022
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancerManish A Shah, Takashi Kojima, Daniel Hochhauser, et al.
International Journal of Cancer|September 30, 2016
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trialFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.
Journal of the National Cancer Institute|September 26, 2015
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal CancerFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.
Cancer|June 5, 2003
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinomaW Fraser Symmans, Mark Ayers, Edwin A Clark, et al.
Lung Cancer (Amsterdam, Netherlands)|February 29, 2024
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782Jair Bar, Emilio Esteban, Delvys Rodríguez-Abreu, et al.
Cancer Medicine|December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G Pfister, Robert I Haddad, Francis P Worden, et al.
Heart Rhythm|August 30, 2023
Multicenter retrospective evaluation of magnetic resonance imaging in pediatric and congenital heart disease patients with cardiac implantable electronic devicesLindsey Gakenheimer-Smith, Zhining Ou, Jinqiu Kuang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2018
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028Patrick A Ott, Yung-Jue Bang, Sarina A Piha-Paul, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
JTO Clinical and Research Reports|February 16, 2023
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLCMarina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
JTO Clinical and Research Reports|October 15, 2025
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]Marina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
Future Oncology (London, England)|July 19, 2022
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancerManish A Shah, Takashi Kojima, Daniel Hochhauser, et al.
International Journal of Cancer|September 30, 2016
Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trialFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.
Journal of the National Cancer Institute|September 26, 2015
A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal CancerFrancesco Sclafani, Tae Y Kim, David Cunningham, et al.
Cancer|June 5, 2003
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinomaW Fraser Symmans, Mark Ayers, Edwin A Clark, et al.
Lung Cancer (Amsterdam, Netherlands)|February 29, 2024
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782Jair Bar, Emilio Esteban, Delvys Rodríguez-Abreu, et al.
Cancer Medicine|December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G Pfister, Robert I Haddad, Francis P Worden, et al.
Heart Rhythm|August 30, 2023
Multicenter retrospective evaluation of magnetic resonance imaging in pediatric and congenital heart disease patients with cardiac implantable electronic devicesLindsey Gakenheimer-Smith, Zhining Ou, Jinqiu Kuang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2018
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028Patrick A Ott, Yung-Jue Bang, Sarina A Piha-Paul, et al.
Pageof 4